OverviewSuggest Edit

Cernostics is a diagnostics company focused on delivering next-generation cancer diagnostics and prognostics through a unique approach to tissue analysis. Cernostics takes a tissue systems biology approach to anatomic pathology. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.

HQPittsburgh, US

Latest Updates

Employees (est.) (Nov 2019)12

Cernostics Office Locations

Cernostics has an office in Pittsburgh
Pittsburgh, US (HQ)
1401 Forbes Ave #302
Show all (1)

Cernostics Financials and Metrics

Summary Metrics

Founding Date


Cernostics total Funding

$15.3 m

Cernostics latest funding size

$2.50 m

Time since last funding

2 years ago

Cernostics investors

Cernostics's latest funding round in March 2018 was reported to be $2.5 m. In total, Cernostics has raised $15.3 m
Show all financial metrics

Cernostics Online and Social Media Presence

Embed Graph

Cernostics News and Updates

Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease

Pittsburgh, PA - (NewMediaWire) - July 01, 2019 - Cernostics, developer of next-generation cancer diagnostics and prognostics, today announced the formation of a distinguished medical advisory board (MAB) including key opinion leaders and world-renowned experts in gastroesophageal reflux diseas…

Cernostics Blogs

TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences

Data presented at ACG, UEGW illustrates the 4th independent validation of TissueCypher performance for risk stratifying non-dysplastic Barrett’s esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD)   PITTSBURGH, Penn., October 22, 2019 — Cernostics, developer of AI-dri…

Research Validates Tissue Pathology Test Predicting Progression in Barrett’s Esophagus

Objective risk assessment guides surveillance and treatment Patients with Barrett’s esophagus (BE) face a low but consequential risk of progression to esophageal adenocarcinoma, for which treatments are limited. Gastroenterologists need reliable methods to assess progression risk in BE patients ….  …

Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019

PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) — Cernostics, developer of next-generation cancer diagnostics and prognostics today announced that the results of an independent study validating the use of its TissueCypher Barrett’s Esophagus Assay in determining the risk of progression to esophageal cance…

Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics

– US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients –    PITTSBURGH, Penn., November 20, 2018 — Cernostics, developer of next-generation cancer diagnostics and prognostics, announced that it has received a U.S. Pa…

Cernostics Frequently Asked Questions

  • When was Cernostics founded?

    Cernostics was founded in 2008.

  • How many employees does Cernostics have?

    Cernostics has 12 employees.

  • Who are Cernostics competitors?

    Competitors of Cernostics include PerkinElmer, Bio-Rad and Quanterix.

  • Where is Cernostics headquarters?

    Cernostics headquarters is located at 1401 Forbes Ave #302, Pittsburgh.

  • Where are Cernostics offices?

    Cernostics has an office in Pittsburgh.

  • How many offices does Cernostics have?

    Cernostics has 1 office.